Our data cannot absolutely support the thesis of a protective effect of these antibodies described in other studies, but we found higher levels in the myocarditis age group of >5–17 years, which presented with less severe adverse events and better LVEF as compared to the other MYC age groups (19, 26). The gene discussed is MYC; the disease is myocarditis.